Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Taking dutasteride every other day works as well as daily and better preserves sexual function.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

In this study, patients with larger prostates were observed to have a higher prevalence of androgenetic alopecia.

This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

In this study, GC/MS analysis revealed variability in the quality of Syrian herbal formulations for BPH, with variations in tocopherol content, presence of parabens, and shortages of certain phytosterols.

In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.

This article reviews the safety of finasteride by examining existing literature and does not report new findings, highlighting the ongoing controversies regarding its adverse effects.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

In this animal study, administering testosterone alongside a 5α-reductase inhibitor counteracted testosterone's effects on prostate enlargement while preserving its beneficial effects on muscle and bone.

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

Finasteride may cause breast enlargement, low testosterone a risk factor.

This article reviews the association between androgenic alopecia and metabolic syndrome, highlighting the importance of early diagnosis and lifestyle changes to manage associated health risks, but reports no new clinical results.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

In this study, finasteride treatment was associated with an increased risk of depression, suicidal ideation, and persistent sexual dysfunction compared to those not treated with the drug.

This study found that urologist prescription practices for three common conditions led to nearly $410 million in excess Medicare Part D spending on higher cost and non-generic drugs in 2014.

Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.

Patients follow treatment well, but many change medicines; good information helps compliance.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

Hair loss can be an early sign of prostate enlargement.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.

This study found that combining D-004 with finasteride results in more significant prevention of testosterone-induced prostate enlargement in rats compared to using either treatment alone.

This study found a positive correlation between androgenetic alopecia severity and enlarged prostate size, with more severe cases showing a higher likelihood of prostate enlargement.